



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 04-183 (400/147))**

In the Application of:)	
)	
McSwiggen et al.)	
)	Examiner: TBD
Serial No.: 10/798,090)	
)	Group Art Unit: 1636
Filing Date: March 11, 2004)	
)	Confirmation No.: 6030
For: RNA Interference Mediated Inhibition of)	
Muscarinic Cholinergic Receptor Gene)	
Expression Using Short Interfering)	
Nucleic Acid (siNA))	

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Third Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. This application is a continuation-in-part of U.S. Patent Application No. 10/757,803, filed January 14, 2004, which is a continuation-in-part of U.S. Patent Application No. 10/720,448, filed November 24, 2003, which is a continuation-in-part of U.S. Patent Application No. 10/693,059, filed October 23, 2003, which is a continuation-in-part of U.S. Patent Application No. 10/444,853, filed May 23, 2003, which is a continuation-in-part of International Patent Application No. PCT/US03/05346, filed February 20, 2003, and a continuation-in-part of International Patent Application No. PCT/US03/05028, filed February 20, 2003, both of which claim the benefit of U.S. Provisional Application No. 60/358,580 filed February 20, 2002, U.S. Provisional Application No. 60/363,124 filed March 11, 2002, U.S. Provisional Application No. 60/386,782 filed June 6, 2002, U.S. Provisional Application No.

60/406,784 filed August 29, 2002, U.S. Provisional Application No. 60/408,378 filed September 5, 2002, U.S. Provisional Application No. 60/409,293 filed September 9, 2002, and U.S. Provisional Application No. 60/440,129 filed January 15, 2003. This application is also a continuation-in-part of US Patent Application No. 10/427,160, filed April 30, 2003 and International Patent Application No. PCT/US02/15876 filed May 17, 2002. All references cited are also listed in the PTO-1449 form enclosed herewith.

As this Information Disclosure Statement is being submitted after receipt of a foreign search report, a copy of the search report is attached herewith.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.


CERTIFICATION UNDER 37 C.F.R. § 1.97(e)

The undersigned hereby certifies that each item of information cited in the present Information Disclosure Statement was cited in an International Search Report from the International Searching Authority in a counterpart international application no more than three months prior to the filing of the present Information Disclosure Statement.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date:

2005 By:


Anita J. Terpstra
Reg. No. 47,132

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

04-183
(400/147)

10/798,090

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

March 11, 2004

Group:

1636

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	00/21560	04/20/00	WO (Alitalo et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	2.	Chernyavsky et al., "Novel singaling pathways mediating reciprocal control of keratinocyte migration and wound epithelialization through M ₃ and M ₄ muscarinic receptors," <i>The Journal of Cell Biology</i> , 166(2):261-272 (2004)
	3.	Davidson et al., "Native <i>Xenopus</i> oocytes express two types of muscarinic receptors," <i>FEBS</i> , 284(2):22-256 (1991)
	4.	Hasan et al., "VEGF antagonists," <i>Oncologic, Metabolic & Endocrine</i> , 703-718 (2001)
	5.	Hollmann et al., "Inhibition of m3 muscarinic acetylcholine receptors by local anaesthetics," <i>British Journal of Pharmacology</i> , 133:207-216 (2001)
	6.	International Search Report for PCT/US2004/027367 mailed September 7, 2005

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.